Parkinson's Disease Program

About OccamzRazor

OccamzRazor is a private, AI-driven drug discovery company targeting neurodegenerative disorders by building comprehensive maps of disease biology. Its platform integrates multi-omics data and neuroscience to identify novel therapeutic targets and candidates, with an initial focus on Parkinson's disease. The company operates in the high-need, high-complexity neurotherapeutics space, aiming to derisk the traditional discovery process through computational biology. As a pre-clinical, pre-revenue entity, its success hinges on platform validation and the progression of its internal pipeline.

About Selonterra

Selonterra is a private, pre-revenue biotech startup pioneering a novel approach to neurodegenerative diseases. The company's platform integrates human genetics with gene expression network analysis to identify unexploited, druggable targets, with initial programs targeting Alzheimer's (APOE4) and Parkinson's disease (SNCA, LRRK2). Led by a team of experienced industry veterans, the company is advancing its lead small molecule compounds through lead optimization towards IND-enabling studies. Selonterra aims to develop accessible, convenient oral therapies that address the root causes of these devastating conditions.

About TreeFrog Therapeutics

TreeFrog Therapeutics is a private, pre-revenue biotech based in Bordeaux, France, operating at the intersection of cell therapy and regenerative medicine. The company's core innovation is the C-Stem™ platform, a scalable encapsulation technology designed to mass-produce high-quality induced pluripotent stem cell (iPSC)-derived therapies in a unique 3D microtissue format, which aims to improve cell survival, dosing, and safety. With a lead allogeneic cell therapy program for Parkinson's disease targeting a first-in-human trial in 2026 and a discovery program in liver disease, TreeFrog pursues a dual business model of advancing its own therapeutic pipeline while out-licensing its enabling C-Stem™ technology to partners. The company is well-capitalized, having raised significant funding, including a recent €30 million loan from the European Investment Bank, to scale its operations and technology.

Therapeutic Areas

Other Parkinson's Disease Drugs